Oncotarget

Research Papers:

Whole-exome sequencing identified genetic risk factors for asparaginase-related complications in childhood ALL patients

Rachid Abaji, Vincent Gagné, Chang Jiang Xu, Jean-François Spinella, Francesco Ceppi, Caroline Laverdière, Jean-Marie Leclerc, Stephen E. Sallan, Donna Neuberg, Jeffery L. Kutok, Lewis B. Silverman, Daniel Sinnett and Maja Krajinovic _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:43752-43767. https://doi.org/10.18632/oncotarget.17959

Metrics: PDF 2663 views  |   HTML 3412 views  |   ?  


Abstract

Rachid Abaji1,7, Vincent Gagné1, Chang Jiang Xu1, Jean-François Spinella1, Francesco Ceppi1, Caroline Laverdière1,2, Jean-Marie Leclerc1,2, Stephen E. Sallan3,4, Donna Neuberg5, Jeffery L. Kutok6, Lewis B. Silverman3,4, Daniel Sinnett1,2 and Maja Krajinovic1,2,7

1 Research Center, Centre Hospitalier Universitaire Sainte-Justine, Montreal, QC, Canada

2 Department of Pediatrics, University of Montreal, Montreal, QC, Canada

3 Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

4 Division of Hematology/Oncology, Children’s Hospital, Boston, MA, USA

5 Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA

6 Department of Pathology, Brigham and Women’s Hospital, Boston, MA, USA

7 Department of Pharmacology, University of Montreal, Montreal, QC, Canada

Correspondence to:

Maja Krajinovic, email:

Keywords: acute lymphoblastic leukemia; asparaginase; exome-wide association; pharmacogenetics; whole-exome sequencing

Received: April 21, 2017 Accepted: April 27, 2017 Published: May 17, 2017

Abstract

Allergy, pancreatitis and thrombosis are common side-effects of childhood acute lymphoblastic leukemia (ALL) treatment that are associated with the use of asparaginase (ASNase), a key component in most ALL treatment protocols. Starting with predicted functional germline variants obtained through whole-exome sequencing (WES) data of the Quebec childhood ALL cohort we performed exome-wide association studies with ASNase-related toxicities. A subset of top-ranking variants was further confirmed by genotyping (N=302) followed by validation in an independent replication group (N=282); except for thrombosis which was not available for that dataset. SNPs in 12 genes were associated with ASNase complications in discovery cohort including 3 that were associated with allergy, 3 with pancreatitis and 6 with thrombosis. The risk was further increased through combined SNPs effect (p≤0.002), suggesting synergistic interactions between the SNPs identified in each of the studied toxicities. Interestingly, rs3809849 in the MYBBP1A gene was associated with allergy (p= 0.0006), pancreatitis (p=0.002), thrombosis (p=0.02), event-free survival (p=0.02) and overall survival (p=0.003). Furthermore, rs11556218 in IL16 and rs34708521 in SPEF2 were both associated with thrombosis (p=0.01 and p=0.03, respectively) and pancreatitis (p=0.02). The association of SNPs in MYBBP1A, SPEF2 and IL16 geneswith pancreatitis was replicated in the validation cohort (p ≤0.05) as well as in combined cohort (p=0.0003, p=0.008 and p=0.02, respectively). The synergistic effect of combining risk loci had the highest power to predict the development of pancreatitis in both cohorts and was further potentiated in the combined cohort (p=1x10-8).The present work demonstrates that using WES data is a successful “hypothesis-free” strategy for identifying significant genetic markers modulating the effect of the treatment in childhood ALL.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 17959